Invizyne Technologies Past Earnings Performance
Past criteria checks 0/6
Invizyne Technologies's earnings have been declining at an average annual rate of -48.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 0.1% per year.
Key information
-48.9%
Earnings growth rate
-44.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 0.1% |
| Return on equity | n/a |
| Net Margin | 731,989.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How Invizyne Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -5 | 3 | 2 |
| 30 Jun 24 | 0 | -4 | 3 | 1 |
| 31 Mar 24 | 0 | -3 | 2 | 1 |
| 31 Dec 23 | 0 | -2 | 1 | 1 |
| 30 Sep 23 | 0 | -1 | 1 | 0 |
| 31 Dec 22 | 0 | -1 | 1 | 0 |
Quality Earnings: IZTC is currently unprofitable.
Growing Profit Margin: IZTC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if IZTC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare IZTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IZTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: IZTC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.